

SUPPLEMENTARY FIGURE LEGENDS

Figure S1. Standard curves for the CXCL10 3-plex Luminex Assay. A CLIA validate luminex assay was established for monitoring total, long and short forms of CXCL10. Standard curves are shown.


Figure S2. Plasma concentration of MMP2 and MMP9 in patients with chronic HCV. (A,B) The plasma concentration of MMP2 (A) and MMP9 (B) was measured using luminex technology. Plasma from chronic non-responders (NR), patients who achieved a sustained virologic response (SVR) and healthy donors, were tested. Each patient is represented with the median indicated by a black bar. Comparison between groups using a two-tailed U-test revealed no statistically significant differences for either analyte.

Figure S3. Plasma concentration of sDPP4 and CXCL10 correlate with elevated liver enzymes in patients with chronic HCV. (A, B) Plasma levels of sDPP4 and CXCL10 are plotted against ALT and AST levels. Spearman correlation coefficients are reported. (C) A relativity network is diagrammed indicating the correlation between DPP activity, sDPP4 plasma concentration, total CXCL10 plasma concentration and the liver enzymes ALT and AST. A spearman correlation matrix was used to determine the correlation coefficient. Lines indicate correlations > 0.5 with a heat map indicating the strength of the correlation. For all correlations shown the $p < 0.05$. NB: **In one of the patients, the coefficient of variance (CV) in the Luminex run failed to reach our cut-off. As a result the plot in part B (sDPP4 vs. ALT) has 10 points and the other two plots (which included CXCL10 as a parameter) only have 9 points.**


Figure S4. Mass spectroscopy analysis of CXCL10 (1-77aa) and CXCL10 (3-77aa). Human recombinant CXCL10 (1-77aa) was digested *in vitro* with recombinant DPP4 to obtain CXCL10 (3-77aa). 0.5µg were spotted in an H4 column for mass spectrometry analysis. The molecular weight difference (red number) between CXCL10 (1-77aa) and CXCL10 (3-77aa) is 0.2 kDa, corresponding to a 2 amino-acid difference.

Figure S1

A



B



C





Figure S2

A



B






Figure S3

A



B



C




Figure S4




Table S1

TABLE S1. Clinical information for patients studied in Figure 6.

Patient	WK12 response to Tx	TEST	METAVIR A	METAVIR F	Age	Weight	T0_ALAT	T0_ASAT	T0_GGT	S0_Viral Load (log)
MC003 T0	NR	LB	A1	F3	46	65	35	38	49	6.09
SG 006 T0	NR	LB	A2	F4	53	66	171	136	235	5.76
CM007 T0	NR	LB	A2	F4	65	81	283	238	317	5.66
CD013 T0	NR	FS	NA	F4	54	62	100	87	130	6.15
FJ015 T0	NR	LB	A3	F4	44	66	NA	NA	162	6.62
VM017 T0	NR	LB	A2	F2	66	65	75	96	117	5.66
GS019 T0	NR	LB	A2	F3	NA	NA	NA	NA	NA	
CF020 T0	NR	NA	NA	F4	59	NA	104	74	147	6.4
CL021 T0	NR	NA	NA	NA	62	102	88	59	84	5.9
LFJ024 T0	NR	LB	A2	F2	53	NA	82	58	95	6.56
AB025 T0	NR	FS	NA	F2	60	104	23	28	29	2.49
CG029 T0	NR	LB	A2	F3	52	65	133	65	263	5.73
FRO 005 T0	EVR	FS	NA	F1	46	70	92	59	24	6.51
SIG 008 T0	EVR	LB	A2	F1	70	NA	60	44	127	6.47
VM009 T0	EVR	LB	A2	F4	68	74	110	86	180	5.79
FS011 T0	EVR	FT	A3	F3	48	87	87	39	20	5.78
LL012 T0	EVR	LB	A1	F3	45	80	213	73	69	4.44
TI018 T0	EVR	FT	A3	F1	33	75	174	74	90	5.61
HM022 T0	EVR	FT	A3	F4	60	80	207	126	131	6.59
DA023 T0	EVR	LB	A2	F4	57	54	98	61	68	6.36
BD026 T0	EVR	LB	A1	F4	50	NA	69	44	53	6.54
CF027 T0	EVR	LB	A2	F3	40	56	72	47	76	6.82
SR028 T0	EVR	NA	NA	NA	NA	NA	NA	NA	NA	NA
1GM2 T0	EVR	NA	NA	NA	54	64	NA	NA	NA	6.3
3LC1 T0	EVR	NA	NA	NA	47	70	29	66	33	6.4
3BB2 T0	EVR	NA	NA	NA	45	76	63	53	116	Pos

NR = non-responder; EVR = early virologic responder

LB = liver biopsy; FT = Fibrotest; FS = Fibroscan; NA = not available

METAVIR A1 = Mild; A2 = moderate; A3 = severe necro-inflammation

METAVIR F1 = minimal scarring; F2 = extended scarring; F3 = bridging fibrosis; F4 = cirrhosis